FDASIA Expedited Approval Provisions Offer Little Help To Ampligen
Executive Summary
Despite Hemispherx’s initial belief that the chronic fatigue syndrome drug might qualify under the FDA Safety and Innovation Act’s language encouraging increased use of accelerated approval, FDA officials suggest the pathway is not an option and the drug’s effect on an intermediate clinical endpoint has not been adequately demonstrated.